|
Karyotype
|
CRL-2336 is highly transformed which is evident from the chromosome count and karyotype description. The modal chromosome number is 100. At least forty-three marker chromosomes, involving nearly every chromosome, were found. Chromosome 1 and chromosome 3 derivative chromosomes were verified using commercial whole chromosome paint (fluorescent in-situ hybridization (FISH)) probes. An acrocentric chromosome with an extra C-band at qter was detected (2 copies per metaphase). There were no normal X chromosomes however at least one derivative X was seen in each cell. The absence of a Y chromosome was verified by QM staining and C-bands. Normal copies of N1, N4, N15, N16 and N18 were absent. More detailed cytogenetic information is available upon request.
|
|
Derivation
|
This cell line was initiated from a primary ductal carcinoma on October 13, 1995, and took 11.5 months to establish This cell line was initiated from a primary ductal carcinoma on October 13, 1995, and took 11.5 months to establish
|
|
Clinical Data
|
23 years adult An EBV transformed lymphoblastoid cell line (HCC1937BL) from the same patient is available as ATCC CRL-2337BRCA1 analysis revealed that the cell line is homozygous for the BRCA1 5382C mutation, whereas the lymphoblastoid cell line derived from the same patient is heterozygous for the same mutation Caucasian female
|
|
Receptor Expression
|
estrogen receptor, negative progesterone receptor, negative
|
|
Oncogene
|
BRCA1 (mutated, insertion C at nucleotide 5382), her2/neu -, p53 -
|
|
Genes Expressed
|
Epithelial glycoprotein 2 (EGP2),cytokeratin 19,BRCA1 (mutated, insertion C at nucleotide 5382), her2/neu -, p53 -,The cells are negative for expression of Her2-neu and for expression of p53.,The cells are negative for expression of estrogen receptor (ER) and progesterone receptor (PR) The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR).
|
|
Comments
|
The tumor was classified as TNM Stage IIB, grade 3 BRCA1 analysis revealed that the cell line is homozygous for the BRCA1 5382C mutation, whereas the lymphoblastoid cell line derived from the same patient is heterozygous for the same mutation This mutation was present in two other family members; an identical sister also developed breast cancer The cell line has an acquired mutation of TP53 with wild-type allele loss; an acquired homozygous deletion of the PTEN gene, and loss of heterozygosity at multiple loci known to be involved in the pathogenesis of breast cancer The cells are negative for expression of Her2-neu and for expression of p53. HCC1937 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19 The cells are negative for expression of estrogen receptor (ER) and progesterone receptor (PR) An EBV transformed lymphoblastoid cell line (HCC1937BL) from the same patient is available as ATCC CRL-2337 |